Recommendations of the Spanish Society of Nephrology for the management of mineral and bone metabolism disorders in patients with chronic kidney disease: 2021 (SEN-MM).

As in 2011, when the Spanish Society of Nephrology (SEN) published the Spanish adaptation to the Kidney Disease: Improving Global Outcomes (KDIGO) universal Guideline on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), this document contains an update and an adaptation of the 2017 KDIGO guidelines to our setting. In this field, as in many other areas of nephrology, it has been impossible to irrefutably answer many questions, which remain pending. However, there is no doubt that the close relationship between the CKD-MBD/cardiovascular disease/morbidity and mortality complex and new randomised clinical trials in some areas and the development of new drugs have yielded significant advances in this field and created the need for this update. We would therefore highlight the slight divergences that we propose in the ideal objectives for biochemical abnormalities in the CKD-MBD complex compared to the KDIGO suggestions (for example, in relation to parathyroid hormone or phosphate), the role of native vitamin D and analogues in the control of secondary hyperparathyroidism and the contribution of new phosphate binders and calcimimetics. Attention should also be drawn to the adoption of important new developments in the diagnosis of bone abnormalities in patients with kidney disease and to the need to be more proactive in treating them. In any event, the current speed at which innovations are taking place, while perhaps slower than we might like, globally drives the need for more frequent updates (for example, through Nefrología al día).

Renal Sympathetic Hyperactivity in Diabetes Is Modulated by 5-HT1D Receptor Activation via NO Pathway.

Renal vasculature, which is highly innervated by sympathetic fibers, contributes to cardiovascular homeostasis. This renal sympathetic outflow is inhibited by 5-HT in normoglycaemic rats. Considering that diabetes induces cardiovascular complications, we aimed to determine whether diabetic state modifies noradrenergic input at renal level and its serotonergic modulation in rats. Alloxan diabetic rats were anaesthetized (pentobarbital; 60 mg/kg i.p.) and prepared for in situ autoperfusion of the left kidney to continuously measure systemic blood pressure (SBP), heart rate (HR), and renal perfusion pressure (RPP). Electrical stimulation of renal sympathetic outflow induces frequency-dependent increases (Δ) in RPP (23.9 ± 2.1, 59.5 ± 1.9, and 80.5 ± 3.5 mm Hg at 2, 4, and 6 Hz, respectively), which were higher than in normoglycaemic rats, without modifying HR or SBP. Intraarterial bolus of 5-HT and 5-CT (5-HT1/5/7 agonist) reduced electrically induced ΔRPP. Only L-694,247 (5-HT1D agonist) reproduced 5-CT inhibition on sympathetic-induced vasoconstrictions, whereas it did not modify exogenous noradrenaline-induced ΔRPP. 5-CT inhibition was exclusively abolished by i.v. bolus of LY310762 (5-HT1D antagonist). An inhibitor of guanylyl cyclase, ODQ (i.v.), completely reversed the L-694,247 inhibitory effect. In conclusion, diabetes induces an enhancement in sympathetic-induced vasopressor responses at the renal level. Prejunctional 5-HT1D receptors, via the nitric oxide pathway, inhibit noradrenergic-induced vasoconstrictions in diabetic rats.

Functionalization of Morin-Loaded PLGA Nanoparticles with Phenylalanine Dipeptide Targeting the Brain.

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, with its incidence constantly increasing. To date, there is no cure for the disease, with a need for new and effective treatments. Morin hydrate (MH) is a naturally occurring flavonoid of the Moraceae family with antioxidant and anti-inflammatory properties; however, the blood-brain barrier (BBB) prevents this flavonoid from reaching the CNS when aiming to potentially treat AD. Seeking to use the LAT-1 transporter present in the BBB, a nanoparticle (NPs) formulation loaded with MH and functionalized with phenylalanine-phenylalanine dipeptide was developed (NPphe-MH) and compared to non-functionalized NPs (NP-MH). In addition, two formulations were prepared using rhodamine B (Rh-B) as a fluorescent dye (NPphe-Rh and NP-Rh) to study their biodistribution and ability to cross the BBB. Functionalization of PLGA NPs resulted in high encapsulation efficiencies for both MH and Rh-B. Studies conducted in Wistar rats showed that the presence of phenylalanine dipeptide in the NPs modified their biodistribution profiles, making them more attractive for both liver and lungs, whereas non-functionalized NPs were predominantly distributed to the spleen. Formulation NPphe-Rh remained in the brain for at least 2 h after administration.

Motivación y expectativas frente a la vacunación de la gripe y la tercera dosis COVID-19 / Motivation and expectations against flu vaccination and third dose of COVID-19

Objetivos:Conocer el grado de motivación y expectativas de población mayor de 70 años adscrita a un centro de salud sobre la primera administración conjunta de vacunas frente a gripe y COVID-19.Conocer la posible relación entre reacciones adversas y expectativas de las/los pacientes acerca de ambas vacunas. Métodos: Estudio descriptivo transversal, con muestra de pacientes mayores de 70 años a los que se les hace una entrevista mediante una encuesta durante la vacunación en el mes de noviembre. El tamaño de la muestra fue de 687 personas. El cuestionario fue elaborado por los investigadores para recoger variables que pudieran ser de interés en la investigación; por ejemplo, el grado de interés en la vacunación de la gripe a través de cuestiones (si el paciente pregunta a su médica/médico o enfermero/enfermera sobre la campaña de vacunación de la gripe o las expectativas que presenta el paciente en la vacunación de la gripe valorando su opinión en la eficacia que presupone de la misma), donde la finalidad era conocer la motivación e intención de vacunarse y la expectativa existente. Resultados: 687 pacientes aceptaron participar en el proyecto, siendo todos ellos mayores de 70 años, dado que esta era su convocatoria para vacunarse. El 87,7% de la población censada acudió a la cita de vacunación. No se tuvo en cuenta ni el sexo ni la edad de los pacientes, solo que fueran mayores de 70 años. La población encuestada creía más en la eficacia de la vacuna de la COVID-19 (87,5%) que en la de la gripe estacional (82,2%), aunque el 93,7% de las personas encuestadas creía firmemente en la eficacia de la vacunación en general. Parecía haber más consenso sobre la eficacia de la vacuna de la COVID-19 que sobre la de la gripe estacional, aunque el 93,7% de las personas encuestadas creía firmemente en la eficacia de la vacunación en general. (AU)

Objective. To ascertain the degree of motivation and expectations of the population over 70-years-old at a health centre on the first co-administration of vaccines against Influenza and COVID-19. To ascertain the possible relationship between adverse reactions and patients' expectations about both vaccines. Methods. Cross-sectional descriptive study, with a sample of patients over 70-years-old who were interviewed by means of a survey during vaccination in November. The sample size was 687 people. The questionnaire was drawn up by the researchers to collect variables that could be of interest in the research. For example, the degree of interest in influenza vaccination by means of questions (whether the patient asks his doctor or nurse about the influenza vaccination campaign, or the patient's expectations regarding influenza vaccination, assessing his opinion on its effectiveness), where the purpose was to ascertain the motivation and intention to be vaccinated and the existing expectation. Results. A total of 687 patients agreed to take part in the project, all of them over 70-years-old in their vaccination call. The first indirect data is that 87.7% of the registered population attended their vaccination appointment. Neither the sex nor the age of the patients was taken into account, except that they were older than 70. The surveyed population believed more in the efficacy of the COVID-19 vaccine, 87.5% than in that of seasonal influenza, 82.2%. However, 93.7% of respondents strongly believed in the efficacy of vaccination in general. The efficacy of the COVID-19 vaccine appears to be more widely agreed upon than for seasonal flu, although 93.7% of those surveyed believed strongly in the efficacy of vaccination in general. Conclusions. The expectations of the population regarding vaccination as a preventive treatment was high. One factor that has an impact when deciding to get vaccinated was fear. (AU)

Effect of sarpogrelate treatment on 5-HT modulation of vascular sympathetic innervation and platelet activity in diabetic rats.

This study aimed to investigate whether the 5-HT2 receptor blockade alters the 5-HT effect on vascular sympathetic neurotransmission and platelet activation in type 1 diabetes. 28-day diabetes was obtained by alloxan (150 mg/kg; s.c.) in male Wistar rats, administering sarpogrelate (5-HT2 blocker; 30 mg/kg/day; p.o.) for 14 days. Blood glucose and body weight were monitored for 28 days. After 4 weeks of diabetes induction, food and drink intake, urine, plasma-platelet 5-HT, and platelet activation were determined in normoglycemic, non-treated diabetic and sarpogrelate-treated diabetic rats. Another set of diabetic rats were pithed to run the vascular sympathetic stimulation or exogenous noradrenaline administration, examining the induced vasoconstrictor responses. Sarpogrelate treatment significantly reduced drink intake and urine, whereas BW gain, hyperglycemia, and food intake were not modified in diabetic rats. The platelet activation and plasma 5-HT concentration were decreased (increasing the stored 5-HT platelet) by 5-HT2 blockade in diabetic animals. The sympathetic-induced vasoconstrictions were higher in non-treated than in sarpogrelate-treated diabetic rats. 5-HT inhibited these vasopressor responses, reproduced exclusively by the 5-HT1/5/7 receptor agonist, 5-CT. The 5-CT-produced inhibition was partly reversed by 5-HT1D or 5-HT7 antagonists (LY310762 or SB-258719, respectively), and totally annulled by the mixture of LY310762+SB-258719. Noradrenaline-caused vasoconstrictions were also decreased by 5-CT. In conclusion, our results reveal that 14-day sarpogrelate treatment improves polydipsia and polyuria, reduces platelet hyperactivation, plasma 5-HT and the vascular sympathetic tone, and changes 5-HT receptors inhibiting noradrenergic drive in diabetic rats: pre and/or postjunctional 5-HT1D/7 are involved in the sympatho-inhibition.

Fluoxetine Treatment Decreases Cardiac Vagal Input and Alters the Serotonergic Modulation of the Parasympathetic Outflow in Diabetic Rats.

Comorbid diabetes and depression constitutes a major health problem, worsening associated cardiovascular diseases. Fluoxetine's (antidepressant) role on cardiac diabetic complications remains unknown. We determined whether fluoxetine modifies cardiac vagal input and its serotonergic modulation in male Wistar diabetic rats. Diabetes was induced by alloxan and maintained for 28 days. Fluoxetine was administered the last 14 days (10 mg/kg/day; p.o). Bradycardia was obtained by vagal stimulation (3, 6 and 9 Hz) or i.v. acetylcholine administrations (1, 5 and 10 µg/kg). Fluoxetine treatment diminished vagally-induced bradycardia. Administration of 5-HT originated a dual action on the bradycardia, augmenting it at low doses and diminishing it at high doses, reproduced by 5-CT (5-HT1/7 agonist). 5-CT did not alter the bradycardia induced by exogenous acetylcholine. Decrease of the vagally-induced bradycardia evoked by high doses of 5-HT and 5-CT was reproduced by L-694,247 (5-HT1D agonist) and blocked by prior administration of LY310762 (5-HT1D antagonist). Enhancement of the electrical-induced bradycardia by 5-CT (10 µg/kg) was abolished by pretreatment with SB269970 (5-HT7 receptor antagonist). Thus, oral fluoxetine treatment originates a decrease in cardiac cholinergic activity and changes 5-HT modulation of bradycardic responses in diabetes: prejunctional 5-HT7 receptors augment cholinergic-evoked bradycardic responses, whereas prejunctional 5-HT1D receptors inhibit vagally-induced bradycardia.

Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes.

AIMS: This study investigated whether fluoxetine treatment changes the 5-HT regulation on vascular sympathetic neurotransmission in type 1 diabetes. MAIN METHODS: Four-week diabetes was obtained by a single alloxan s.c. administration in male Wistar rats, administering fluoxetine for 14 days (10 mg/kg/day; p.o.). Systolic blood pressure, heart rate, glycaemia, body weight (BW) evolution, creatinine, and blood urea nitrogen (BUN) were monitored. Afterward, rats were pithed to perform the vascular sympathetic stimulation. 5-HT1A/1D/2A receptors expression was analysed by Western blot in thoracic aorta. Both i.v. norepinephrine and the electrical stimulation of the spinal sympathetic drive evoked vasoconstrictor responses. KEY FINDINGS: Fluoxetine treatment significantly reduced the BW gain, hyperglycaemia, creatinine, and BUN in diabetic rats. The electrical-produced vasopressor responses were greater in untreated than in fluoxetine-treated diabetic rats. 5-HT decreased the sympathetic-produced vasopressor responses. While 5-CT, 8-OH-DPAT and L-694,247 (5-HT1/7, 5-HT1A and 5-HT1D agonists, respectively) reproduced 5-HT-evoked inhibition, the 5-HT2 activation by α-methyl-5-HT augmented the vasoconstrictions. The 5-CT sympatho-inhibition was reversed by 5-HT1A plus 5-HT1D antagonists (WAY-100,635 and LY310762, respectively), whereas ritanserin (5-HT2A antagonist) blocked the α-methyl-5-HT potentiating effect. Norepinephrine-generated vasoconstrictions were increased or diminished by α-methyl-5-HT or 5-CT, respectively. 5-HT1A/1D/2A receptors were expressed at vascular level, being 5-HT1A expression increased by fluoxetine in diabetic rats. SIGNIFICANCE: Our findings suggest that fluoxetine improves metabolic and renal profiles, changes the vasopressor responses, and 5-HT receptors modulating sympathetic activity in diabetic rats: 5-HT1A/1D are involved in the sympatho-inhibition, while 5-HT2A is implicated in the sympatho-potentiation, being both effects pre and/or postjunctional in nature.

Variantes anatómicas del tubérculo de Lister. Presentación de una clasificación imagenológica y su utilidad clínica / Anatomical variants of Lister's tubercle. Presentation of an imaging classification and its clinical utility

Objetivo: Evaluar, en forma retrospectiva, las diferentes variantes de los tubérculos de Lister y el extensor largo del pulgar en imágenes de resonancia magnética de muñecas y, sobre la base de dichos hallazgos, proponer variables a la clasificación. Materiales y métodos: Estudio retrospectivo utilizando imágenes de resonancia magnética entre el 1 de marzo y el 10 de noviembre de 2019. Se incluyeron imágenes de muñeca de pacientes sanos (cortes axiales, sagitales y coronales de 1 mm de espesor), >18 años, sin fractura de muñeca o del carpo, previa o actual, y se excluyó a quienes no cumplían estos criterios. Se analizaron el tubérculo de Lister, la altura de los picos radial y cubital, el ángulo, la longitud del tubérculo, la profundidad de los valles y la altura del tabique. Se evaluó el extensor largo del pulgar analizando la altura, el espesor, la superficie y la presencia o no inflamación asociada. Resultados: Se analizaron 500 imágenes de muñeca, y se obtuvieron 11 subtipos de tubérculo de Lister: 411 tipo 1, 58 tipo 2 y 26 tipo 3. Dentro de estos, el más frecuente fue el tipo 1B. El 26,6% tenía inflamación asintomática en el tercero y cuarto compartimento. Conclusiones: El tubérculo de Lister es importante en muchos procedimientos y sirve como punto de referencia anatómico; por lo tanto, es preciso conocer su patrón más frecuente y sus variantes anatómicas. Proponemos una ampliación de la clasificación, adicionando nuevos tipos de tubérculo por conocer y su relación con el extensor largo del pulgar. Nivel de Evidencia: IV

Objective: To retrospectively evaluate the different variants of Lister's tubercle (LT) and extensor pollicis longus (EPL) using magnetic resonance imaging (MRI) of the wrists, and based on these findings propose variables for classification. Materials and Methods: Retrospective study using images from MRI database files between 03/01/19 to 11/10/19. We included MRI of the wrist of healthy patients (axial, sagittal, and coronal slices of 1 mm thickness) who were older than 18 years, with no history of previous or current wrist or carpal fracture, excluding those who did not meet these criteria. We analyzed LT, height of the radial and ulnar peaks, the angle, tubercle length, depth of the grooves and septum height. We evaluated the EPL, analyzing the height, thickness, surface, and presence of associated inflammation. Results: We evaluated 500 MRI of the wrist, obtaining 11 different subtypes of LT. We found 411 type 1 Lister tubercles, 58 type 2, and 26 type 3. Among these, the most frequent were types 1b. 26.6% presented asymptomatic inflammation in 3rd and 4th compartments. Conclusion: Lister's tubercle is of importance in many procedures and serves as an anatomical landmark, meriting to know its most frequent pattern and its anatomical variants. We propose an extension of the classification, adding new types of tubercles to be known and their relationship with the EPL. Level of Evidence: IV

Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment.

Given the interconnection between depressive and cardiovascular disorders, we investigated whether antidepressant treatment (fluoxetine) modifies the serotonergic influence on rat vascular noradrenergic outflow. Twelve-week-old male Wistar rats received fluoxetine treatment (10 mg/kg/day; p.o.) for 14 days; then, they were pithed and prepared for sympathetic stimulation. Vasopressor responses were obtained by electrical stimulation of the sympathetic outflow (0.1, 0.5, 1, and 5 Hz) or i.v. noradrenaline (NA; 0.01, 0.05, 0.1, and 0.5 µg/kg). In fluoxetine-treated group, the electrical-induced vasoconstrictions were lower compared to non-treated rats. Intravenous infusion of 5-HT (10 µg/kg/min) inhibited the sympathetically-induced vasoconstrictions. Only 5-CT, 8-OH-DPAT and L-694,247 (5-HT1/7, 5-HT1A and 5-HT1D agonists, respectively) mimicked 5-HT-induced inhibition, while α-methyl-5-HT (5-HT2 agonist) increased the vasopressor responses. The inhibitory effect of 5-HT was: a) no modified by SB269970 (5-HT7 antagonist); b) abolished by WAY-100,635 (5-HT1A antagonist) plus LY310762 (5-HT1D antagonist); and c) potentiated by ritanserin (5-HT2A receptor antagonist). The vasoconstrictions induced by exogenous NA were not modified by 5-CT but were increased by α-methyl-5-HT. Our results suggest that fluoxetine treatment decreases NA release at vascular level and changes 5-HT modulation on rat vascular noradrenergic neurotransmission, inducing sympatho-inhibition via prejunctional 5-HT1A/1D receptors, and sympatho-potentiation via pre and/or postjunctional 5-HT2A receptors.

Extracellular water/total body water ratio as predictor of mortality in hemodialysis patients.

BACKGROUND: Overhydration is a predictor of mortality in hemodialysis (HD) patients. Bioimpedance spectroscopy (BIS) is used to determine the body composition. Extracellular Water/Total Body Water (ECW/TBW) ratio has been proposed to predict mortality. METHODS: Multicenter, prospective, observational, proof-of-concept study to estimate the impact of ECW/TBW in global and cardiovascular mortality and the relationship with cardiovascular biomarkers. The study included 60 patients (mean age, 71.8 ± 11.4 years; mean time on HD, 52.3 ± 30.8 months) with a median follow-up of 30.5 months (IQ range, 17.2-34 months). RESULTS: Post-dialysis ECW/TBW was directly associated with NT-proBNP and cTnT. During the study 28 patients died, most of them (43%) due to cardiovascular events. Compared to the survivors, these subjects had a higher post-dialysis ECW/TBW ratio (p = 0.006), while for cardiovascular mortality the only significant difference was a higher pre-dialysis ECW/TBW. The ability of post-dialysis ECW/TBW ratio to predict all-cause mortality had an area under the ROC curve (AUC) of 0.71 (CI 95%, 0.57-0.81; p = 0.002), with a cutoff point of 0.5023. For cardiovascular mortality the AUC was 0.66 (CI 95%, 0.52-0.77; p = 0.045), with a cutoff point of 0.4713. CONCLUSIONS: The post-dialysis ECW/TBW ratio measured by BIS can be a predictor of all-cause and cardiovascular mortality.

How to improve adherence the captors of phosphorus on hemodialysis: Experience in real life with sucroferric oxyhydroxide / Cómo mejorar la adherencia a los captores del fosforo en hemodiálisis: experiencia en vía real con oxihidróxido sucroférrico

INTRODUCTION: The lack of adherence to phosphate -binders (PB) is the most important factor in not achieving the objectives of serum phosphorus (sP). Studies in the real-world population are needed to understand the influence of PBs on adherence and how to modify it. METHODS: Prospective study conducted during 3 months in usual clinical practice. Out of 105 hemodialysis patients, 57 were switched to SFOH and 48 maintained their baseline treatment (control group). sP levels and the percentage of patients with sP levels < 5mg/dl were compared. Adherence before and after introduction of SFOH, number of pills of PB, preferences in the administration mode and side effects were analyzed. RESULTS: The percentage of patients with controlled sP (< 5 mg/dl) increased significantly in the SFOH users' group (62.1-92.9%, p < 0.001), but not in the control group (83-83.3%, p = NS). The average of daily tablets decreased significantly in the SFOH group (7.2-2.3 comp, p < 0.001), but not in the control group (5.6-5.6, p = NS) and 100% of the patients used only one PB in SFOH group. The use of SFOH increased the adherence according to the SMAQ questionnaire (57.8-84.3%; OR 13.1, p < 0.001). The possibility to choose the preferred mode of administration (split-swallowing 89% compared to chewing 11%), improved the acceptance (44.7-78%). 14% of the patients experienced side effects and in 5.2% SFOH was discontinued for this reason. CONCLUSIONS: SFOH controlled serum sP in 93% of patients, 100% in monotherapy, and with fewer tablets. The exploration and adaptation of preferences in the mode of administration influenced the acceptance of the drug by the patient and, probably, the future adherence

INTRODUCCIÓN: La falta de adherencia a los captores del fósforo es el factor más importante para no lograr los objetivos del fósforo sérico (Ps). Se necesitan estudios en la población del mundo real para comprender la influencia de los CP sobre la adherencia y como modificarla. OBJETIVOS: Evaluar la eficacia y la adherencia de un nuevo CP, oxihidróxido sucroférrico (OHSF) en pacientes en hemodiálisis y la influencia de un cambio en el modo de administración del fármaco sobre la aceptación del mismo. MÉTODOS: Estudio prospectivo realizado durante 3 meses en práctica clínica habitual. De 105 pacientes de hemodiálisis, 57 pacientes con P mal controlado (p < 5 mg/dl) fueron cambiados a OHSF y 48 mantuvieron su tratamiento inicial (grupo control). Se compararon los niveles de Ps y el porcentaje de pacientes con niveles de Ps < 5 mg/dl. Se analizó la adherencia antes y después de la introducción de OHSF, el número de comprimidos de captores del P, los efectos secundarios y el grado de aceptación del fármaco tras ofrecer varias alternativas en el modo de administración. RESULTADOS: El porcentaje de pacientes con P controlado (< 5 mg/dl) aumentó significativamente a los 3 meses de seguimiento en el grupo de pacientes con OHSF (62,1 al 92,9%; p < 0,001), pero no en el grupo de control (83 al 83,3%; p = NS). El promedio de comprimidos diarios disminuyó significativamente en el grupo OHSF (7,2 a 2,3 comprimidos; p < 0,001), pero no en el grupo control (5,6 a 5,6; p = NS) y todos los pacientes en tratamiento con OHSF se controlaron con monoterapia. El uso de OHSF aumentó la adherencia según el cuestionario SMAQ (57,8 al 84,3%; OR: 13,1; p < 0,001). La posibilidad de elegir el modo de administración preferido (cortar-tragar 89% en comparación con masticar 11%) mejoró la aceptación (44,7 al 78%) de los pacientes. El 14% de los pacientes experimentaron efectos secundarios y en 5,2% se suspendió el OHSF por esta razón. CONCLUSIONES: OHSF controló el P sérico en el 93% de los pacientes, siendo la totalidad de ellos en monoterapia, y con menor número de comprimidos a corto plazo. La exploración y adaptación de las preferencias en el modo de administración influyó en la aceptación del fármaco por parte del paciente y, probablemente en la adherencia futura

How to improve adherence the captors of phosphorus on hemodialysis: Experience in real life with sucroferric oxyhydroxide.

INTRODUCTION: The lack of adherence to phosphate -binders (PB) is the most important factor in not achieving the objectives of serum phosphorus (sP). Studies in the real-world population are needed to understand the influence of PBs on adherence and how to modify it. METHODS: Prospective study conducted during 3 months in usual clinical practice. Out of 105 hemodialysis patients, 57 were switched to SFOH and 48 maintained their baseline treatment (control group). sP levels and the percentage of patients with sP levels <5mg/dl were compared. Adherence before and after introduction of SFOH, number of pills of PB, preferences in the administration mode and side effects were analyzed. RESULTS: The percentage of patients with controlled sP (<5mg/dl) increased significantly in the SFOH users' group (62.1-92.9%, p<0.001), but not in the control group (83-83.3%, p=NS). The average of daily tablets decreased significantly in the SFOH group (7.2-2.3 comp, p<0.001), but not in the control group (5.6-5.6, p=NS) and 100% of the patients used only one PB in SFOH group. The use of SFOH increased the adherence according to the SMAQ questionnaire (57.8-84.3%; OR 13.1, p<0.001). The possibility to choose the preferred mode of administration (split-swallowing 89% compared to chewing 11%), improved the acceptance (44.7-78%). 14% of the patients experienced side effects and in 5.2% SFOH was discontinued for this reason. CONCLUSIONS: SFOH controlled serum sP in 93% of patients, 100% in monotherapy, and with fewer tablets. The exploration and adaptation of preferences in the mode of administration influenced the acceptance of the drug by the patient and, probably, the future adherence.

Nueva información sobre interacciones de captores de fósforo con la vitamina K / New information on phosphate binder interactions with vitamin K

No disponible

Interacciones farmacológicas de los captores del fósforo / Pharmacological interactions of phosphate binders

No disponible

Tratamiento de multiples recesiones en el sector estético mediante el empleo de la técnica bilaminar: descripción de la técnica quirúrgica y resultados / Treatment of multiple recessions in the aesthetic sector through the use of the bilaminar technique: description of the surgical technique and results

La recesión gingival, definida como la denudación parcial radicular por el desplazamiento apical del margen gingival involucra al hueso alveolar vestibular y a la encía libre situada sobre él. Las recesiones gingivales fueron clasificadas por Miller según el pronóstico para el recubrimiento radicular. Se han propuesto diferentes procedimientos quirúrgicos y diseños de colgajos para el tratamiento de recesiones múltiples en área estética. En este trabajo se presentan y describen el tratamiento de múltiples recesiones gingivales adyacentes que afectan a la zona estética, las cuales se trataron mediante la técnica bilaminar de injerto de tejido conectivo y derivados de la matriz del esmalte en combinación con un colgajo de reposición coronal. La utilización de la técnica bilaminar dio lugar a un recubrimiento radicular satisfactorio en el tratamiento de múltiples recesiones gingivales

Gingival recession, defined as partial radicular denudation by the apical displacement of the gingival margin, involves the vestibular alveolar bone and the free gingiva located above it. Gingival recessions were classified by Miller as the prognosis for root coverage. Different surgical procedures and flap designs have been proposed for the treatment of multiple recessions in the aesthetic area. This paper presents and describes the treatment of multiple adjacent gingival recession affecting the aesthetic zone, which were treated by bilaminar technique connective tissue graft and enamel matrix derivatives in combination with a coronally advanced flap. The use of bilaminar technique resulted in a satisfactory root coverage in treating multiple gingival recession

5-aminoisoquinoline improves renal function and fibrosis during recovery phase of cisplatin-induced acute kidney injury in rats.

The aim of the present study is to analyze the effects of 5-aminoisoquinoline (5-AIQ), a poly(ADP-ribose) polymerase-1 (PARP1) inhibitor, over renal dysfunction and fibrosis during recovery phase of cisplatin (CisPt)-induced acute kidney injury (AKI) in rats. Male Wistar rats were distributed in three groups (n=8 each group): control, CisPt, and CisPt + 5-AIQ. Control and CisPt groups received a subcutaneous injection of either saline or 7 mg/kg CisPt, respectively. CisPt + 5-AIQ group received two intraperitoneal injections of 10 mg/kg 5-AIQ 2 h before and 24 h after CisPt treatment. Thirteen days after the treatment, rats were housed in metabolic cages and 24-h urine collection was made. At day 14, CisPt-treated rats showed increased diuresis, N-acetyl-ß-d-glucosaminidase (NAG) excretion, glucosuria and sodium fractional excretion (NaFE), and decreased creatinine clearance (CrCl). 5-AIQ significantly increased CrCl and decreased NAG excretion, glucosuria, and NaFE. In plasma, CisPt increased sodium, urea, and creatinine concentrations, while 5-AIQ treatment decreased these variables to the levels of control group. 5-AIQ completely prevented the body weight loss evoked by CisPt treatment. CisPt also induced an increased renal expression of PAR polymer, α-smooth muscle actin (α-SMA), transforming growth factor-ß1 (TGF-ß1), and collagen-IV. These variables were decreased in CisPt + 5-AIQ group. Tubular lesions and renal fibrosis were also decreased by 5-AIQ treatment. We conclude that inhibition of PARP1 with 5-AIQ can attenuate long-term nephrotoxic effects associated with the CisPt treatment, preventing renal dysfunction and body weight decrease and ameliorating tubular lesions and collagen deposition.

Aortic Customized Stent-Graft Treatment of Postnephrectomy Renal Pedicle Arteriovenous Fistula.

A postnephrectomy renal acquired arteriovenous fistula (AVF) is a rare clinical entity that may cause high-output heart failure. Most of the cases are identified time along after surgery. We present a case of a postnephrectomy renal AVF treated with aortic customized stent-graft.

Effect of the diet traditional and non-traditional on the respiration and excretion in larvae of white shrimp Litopenaeus vannamei / Efecto de la dieta tradicional y no tradicional en la respiración y excreción de larvas de camarón blanco Litopenaeus vannamei

Objective. It was studied the respiration and ammoniacal excretion of zoeas and mysis of Litopenaeus vannamei fed with the diet used traditionally (of microalgae and nauplios of Artemia) and another alternative (not traditional) of microalgae with rotifers. Materials and methods. After four hours the oxygen consumption and ammonia excretion in BOD bottles with 60 larvae (closed respirometers) was estimated. The concentrations of O2 and NH4+ were measured with an electrode polarográfico in the first case and with the indophenol blue technique for the second. Results. In zoea, oxygen consumption increased with development and showed statistical differences (p=0.023). In mysis, the oxygen consumption were significance in the traditional diet, whereas no differences were alternative (p=0.003). In both stages for the ammoniacal excretion increased development stage and there were detected statistical difference (p<0.001), although to the diets were not noticed significant differences. Conclusions. A higher energy absorption for zoea (I, II y III) what mysis (I, II y III) larvae was obtained, this is likely an interaction between rates of respiration and excretion caused by variations in the efficiency of absorption by the larvae. The weights obtained in both larvae were not supplied with differences between diets.

Objetivo. Se analizó la respiración (O2) y excreción amoniacal (NH4+) en larvas zoea y mysis de camarón blanco Litopenaeus vannamei, alimentadas con las dietas tradicionales (microalgas y nauplios de Artemia) y no tradicionales (microalgas y rotíferos). Materiales y métodos. A las cuatro horas de experimentación se estimó el consumo de oxígeno y la excreción de amonio en botellas BOD con 60 larvas (respirómetros cerrados). La concentración de O2 se midió con un electrodo polarográfico y la NH4+ se determinó con la técnica de azul de Indofenol. Resultados. En zoea, el consumo de oxígeno incrementó con el desarrollo y se presentaron diferencias estadísticas (p=0.023). En mysis, los consumos de oxígeno presentaron una significancia entre la dieta tradicional, mientras en la alternativa no se obtuvieron diferencias (p=0.003). La excreción en ambos estadios larvales aumentó con la fase y se detectaron diferencias estadísticas (p<0.001), aunque no se registraron diferencias significativas en las larvas respecto a las dietas suministradas. Conclusiones. Se obtuvo una absorción de energía superior para las zoea (I, II y III) que mysis (I, II y III), esto probablemente a una interacción entre las tasas de respiración y de excreción provocada por variaciones en la eficiencia de absorción de las larvas. Los pesos obtenidos en ambas larvas no resultaron con diferencias entre las dietas suministradas.